Eton Pharmaceuticals, Inc.
NASDAQ•ETON
CEO: Mr. Sean E. Brynjelsen
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2018-11-13
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Contact Information
21925 W. Field Parkway, Suite 235, Deer Park, IL, 60010-7278, United States
847-787-7361
Market Cap
$489.42M
P/E (TTM)
-118.9
vs Industry 16.6
Dividend Yield (TTM)
--
52W High
$23.00
52W Low
$8.24
52W Range
1.6
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2017-2024
Financial Dashboard
Q2 2025 Data
Revenue
$18.93M+108.60%
4-Quarter Trend
EPS
-$0.10-19.92%
4-Quarter Trend
FCF
$7.96M+534.18%
4-Quarter Trend
Earnings Highlights
Key Highlights
No Data Available
Risk Factors
No Data Available
Outlook
No Data Available
Peer Comparison
Revenue (TTM)
RIGL
LXRXETONGross Margin (Latest Quarter)
ALMS
OCGNLXRXKey Metrics
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
+22.4%
Strong Growth
4-Quarter Net Income CAGR
N/M
Profitability Shift Observed
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Reports
All Years